Givinostat: Targeting the Downstream Disease in Duchenne Muscular Dystrophy

Written by The Life Science Feed Editorial Team · Edited by Mara Voss

Duchenne muscular dystrophy (DMD) remains a devastating X-linked genetic disorder, characterised by progressive muscle degeneration and weakness. While gene therapies and exon-skipping strategies aim to correct the underlying genetic defect, many patients are ineligible or present with advanced disease. This leaves a significant unmet need for therapies that can mitigate the downstream effects of dystrophin deficiency, regardless of the specific mutation.

Givinostat, a histone deacetylase (HDAC) inhibitor, represents one such non-genetic approach, focusing on the pathological consequences of the disease rather than the primary genetic cause. Its mechanism of action targets inflammation and fibrosis, key drivers of muscle damage in DMD.

KEY TAKEAWAYS

- The Pivot: Givinostat offers a non-genetic strategy for Duchenne muscular dystrophy, focusing on the downstream pathology of inflammation and fibrosis.
- The Data: Specific numeric results are not available for this general discussion.
- The Action: Clinicians should consider the potential for non-genetic approaches to complement or provide alternatives to mutation-specific therapies in DMD.

Duchenne muscular dystrophy results from mutations in the DMD gene, leading to a deficiency of the protein dystrophin. This absence destabilises the sarcolemma, making muscle fibres highly susceptible to damage during contraction. The repeated cycles of degeneration and regeneration eventually exhaust the muscle's regenerative capacity, leading to progressive fibrosis and adipose tissue infiltration, which are hallmarks of advanced DMD. The inflammatory response, initially protective, becomes chronic and maladaptive, further contributing to muscle damage and fibrosis. Standard-of-care corticosteroids aim to dampen this inflammation, but their long-term use is associated with significant side effects.

Givinostat is an oral small molecule that inhibits histone deacetylases. HDACs are enzymes that remove acetyl groups from histone proteins, leading to a more condensed chromatin structure and reduced gene expression. By inhibiting HDACs, givinostat promotes histone acetylation, which can alter the expression of genes involved in inflammation, fibrosis, and muscle regeneration. This mechanism positions it as a broad-acting agent, potentially beneficial across various DMD genotypes, unlike mutation-specific therapies such as exon-skipping drugs. The drug aims to reduce inflammation and fibrosis, preserve muscle integrity, and slow disease progression.

The Rationale for HDAC Inhibition in DMD

The rationale for targeting HDACs in DMD stems from their role in regulating gene expression critical to muscle health and disease pathogenesis. In DMD, dysregulation of gene expression contributes to the inflammatory and fibrotic processes that drive muscle degeneration. HDAC inhibitors can modulate these pathways by increasing the expression of beneficial genes and suppressing detrimental ones. For instance, increased histone acetylation can lead to the upregulation of genes involved in muscle repair and regeneration, while simultaneously downregulating pro-inflammatory and pro-fibrotic genes. This dual action makes HDAC inhibitors an attractive therapeutic strategy for a complex, multi-factorial disease like DMD.

Inflammation is a central component of DMD pathology. Dystrophin-deficient muscle fibres are prone to damage, triggering an immune response that, over time, becomes chronic and destructive. Macrophages, T cells, and other immune cells infiltrate the muscle, releasing cytokines and chemokines that perpetuate inflammation and contribute to fibrosis. Givinostat's ability to modulate inflammatory pathways, including the NF-κB pathway, is thought to reduce this chronic inflammation, thereby protecting muscle fibres from ongoing damage. This is a critical distinction from therapies that only address the genetic defect, as the inflammatory cascade is a downstream consequence that requires independent intervention.

Fibrosis, the excessive accumulation of connective tissue, is another major contributor to muscle weakness and loss of function in DMD. As muscle fibres degenerate, they are replaced by fibrotic tissue, which impedes muscle contraction and regeneration. Givinostat has been shown to reduce fibrotic markers and improve muscle architecture in preclinical models of DMD. This anti-fibrotic effect is mediated through the modulation of pathways such as the transforming growth factor-beta (TGF-β) pathway, a key driver of fibrosis. By mitigating fibrosis, givinostat could help preserve muscle function and delay the progression to severe immobility. For a deeper understanding of how non-genetic approaches are evolving, consider why transthyretin amyloid cardiomyopathy remains underdiagnosed, as it also highlights the need for therapies addressing downstream effects.

Clinical Development and Patient Selection

The development of givinostat has focused on its potential to slow disease progression in ambulatory patients with DMD. These patients, typically younger boys, still retain significant muscle function, making them ideal candidates for therapies aimed at preserving muscle mass and delaying functional decline. The drug is administered orally, which offers a practical advantage for long-term treatment compared to intravenous therapies. Patient selection for givinostat, or any non-genetic approach, often considers factors such as age, ambulatory status, and corticosteroid use, as these can influence treatment response and study outcomes.

The primary endpoints in clinical evaluations of givinostat typically involve measures of muscle function and strength, such as changes in the North Star Ambulatory Assessment (NSAA) score, timed function tests (e.g., 4-stair climb, 10-meter walk/run), and quantitative muscle strength assessments. Secondary endpoints often include biomarkers of muscle damage, inflammation, and fibrosis, as well as assessments of muscle fat fraction using MRI. These endpoints are designed to capture both functional improvements and biological effects of the drug. The aim is to demonstrate a clinically meaningful benefit in slowing the relentless progression of the disease.

Safety and tolerability are paramount in a chronic condition like DMD, especially given the long-term nature of treatment. Common adverse events associated with HDAC inhibitors can include gastrointestinal disturbances, thrombocytopenia, and QT prolongation. Careful monitoring for these side effects is essential during treatment. The overall safety profile

must be weighed against the potential benefits in a disease with such a severe prognosis. Clinicians managing these complex cases often rely on comprehensive resources, such as the Oxford Handbook of Paediatrics, for guidance on rare diseases and their management.

The Role of Non-Genetic Therapies in a Evolving Landscape

The emergence of gene therapies and exon-skipping drugs has transformed the treatment landscape, the market for DMD therapies, offering the promise of addressing the root genetic cause. But these therapies are often mutation-specific, limiting their applicability to a subset of patients. Challenges such as immune responses to viral vectors and the need for early intervention mean that many patients will still require alternative or complementary treatments. Non-genetic approaches, like givinostat, fill a critical gap by targeting the downstream pathology that is common to all forms of DMD, regardless of the specific mutation. This broad applicability is a significant advantage, particularly for patients who are not candidates for genetic therapies or those with advanced disease where genetic correction may be less effective.
Combination therapy is another area of increasing interest in DMD. It is plausible that combining a non-genetic agent like givinostat with a mutation-specific therapy could yield synergistic benefits, addressing both the genetic defect and its pathological consequences. For example, a gene therapy might restore dystrophin expression, while givinostat simultaneously reduces inflammation and fibrosis, creating a more favourable environment for muscle regeneration and preservation. This multi-pronged approach reflects the complex nature of DMD and the need for comprehensive treatment strategies. The field is also exploring new approaches to glucocorticoid dosing in other conditions, which may offer insights into managing chronic inflammation in DMD with fewer side effects.
Still, the long-term impact of these non-genetic therapies on disease progression and quality of life remains a key area of investigation. While short-term functional improvements are important, the ultimate goal is to significantly alter the natural history of DMD, extending ambulation and improving overall survival. The challenge lies in demonstrating sustained benefits over many years, particularly in a disease with such a variable and progressive course. The open-label design is the obvious caveat in many early studies, and larger, well-controlled trials are essential to solidify the evidence base. The trial was not powered to detect differences in all subgroups, and that gap matters for understanding the full scope of benefit.

> **CLINICAL IMPLICATIONS**
>
> The arrival of givinostat and similar non-genetic approaches marks a necessary evolution in Duchenne muscular dystrophy management. For too long, the focus has been almost exclusively on the genetic defect, leaving a substantial population of patients with limited options. These therapies offer a chance to mitigate the relentless muscle damage that defines DMD, regardless of the specific mutation.
> Clinicians should begin to integrate the concept of downstream disease modification into their treatment paradigms. While gene therapies hold immense promise, they are not a panacea. A significant portion of the DMD population will either be ineligible or will require additional interventions to manage the chronic inflammation and fibrosis that drive disease progression.
> The industry's shift towards these broader-acting agents is a pragmatic response to the complexities of DMD. It acknowledges that even with genetic correction, the muscle environment remains hostile. Developing therapies that can calm this environment, reduce fibrosis, and support muscle integrity is crucial for improving

> long-term outcomes for all patients, not just those with amenable mutations.
> The goal is to extend ambulation and improve the quality of life for these patients. Non-genetic therapies, by addressing the common pathological pathways, provide a vital complement to the more targeted genetic interventions, offering a more comprehensive strategy against this devastating disease.

EDITORIAL & AI STANDARDS

AI tools are used solely to structure and summarise evidence from peer-reviewed primary sources. No AI-generated conclusions appear in The Life Science Feed without editor verification against the primary source.

REFERENCES

1. 1. Giovarelli M, Zecchini S, Catarinella G, et al. Givinostat as metabolic enhancer reverting mitochondrial biogenesis deficit in Duchenne Muscular Dystrophy. Pharmacol Res. 2021;170:105751. doi:10.1016/j.phrs.2021.105751
2. 2. Consalvi S, Saccone V, Mozzetta C. Histone deacetylase inhibitors: a potential epigenetic treatment for Duchenne muscular dystrophy. Epigenomics. 2014;6(5):547-60. doi:10.2217/epi.14.36

LICENCE & RIGHTS

MEDICAL DISCLAIMER

This content is intended for healthcare professionals only and does not constitute medical advice. Clinical decisions must be made by qualified practitioners based on individual patient circumstances.

FOLLOW THE LIFE SCIENCE FEED

Instagram @lifesciencefeed **LinkedIn** linkedin.com/company/thelifesciencefeed

thelifesciencefeed.com